Catalyst Biosciences, Inc. (CBIO)
Stock Price:
$5.29 USD
-0.37 (-6.54%)
Updated Aug 11, 2020 4:00 PM EDT - Market closed
After-hours: $5.51 +0.22 (4.16%) Aug 11, 4:16 PM
Key Info
| Market Cap |
116.71M |
| Revenue (ttm) |
18.02M |
| Net Income (ttm) |
-47.62M |
| Shares Out |
22.06M |
| EPS (ttm) |
-3.37 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 11, 2020 |
| Last Price |
$5.29 |
| Previous Close |
$5.66 |
| Change ($) |
-0.37 |
| Change (%) |
-6.54% |
| Day's Open |
5.65 |
| Day's Range |
5.24 - 5.66 |
| Day's Volume |
394,025 |
| 52-Week Range |
3.43 - 8.94 |
More Stats
| Market Cap |
116.71M |
| Enterprise Value |
915,270 |
| Earnings Date (est) |
Oct 29, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
22.06M |
| Float |
19.61M |
| EPS (basic) |
-3.43 |
| EPS (diluted) |
-3.37 |
| FCF / Share |
-2.08 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.65M |
| Short Ratio |
2.40 |
| Short % of Float |
6.81% |
| Beta |
2.25 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
6.48 |
| PB Ratio |
1.22 |
| Revenue |
18.02M |
| Operating Income |
-49.61M |
| Net Income |
-47.62M |
| Free Cash Flow |
-37.15M |
| Net Cash |
115.80M |
| Net Cash / Share |
5.25 |
| Gross Margin |
-243.34% |
| Operating Margin |
-275.25% |
| Profit Margin |
-264.20% |
| FCF Margin |
-206.10% |
| ROA |
-27.62% |
| ROE |
-47.13% |
| ROIC |
-95.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
3 |
| Overweight |
1 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$20.25*
(282.80% upside)
Low
18.0
Current: $5.29
High
23.0
Target: 20.25
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | - | - | 1.02 | 0.40 | 1.75 | 1.81 | 0.52 | 57.86 | 97.64 | 85.71 |
| Revenue Growth | - | - | 155.14% | -77.2% | -3.47% | 246.65% | -99.1% | -40.74% | 13.91% | - |
| Gross Profit | - | - | 1.02 | 0.40 | 1.75 | 1.81 | 0.52 | 57.86 | 97.64 | 85.71 |
| Operating Income | -57.28 | -33.83 | -21.82 | -20.42 | -13.80 | -7.51 | -10.12 | -8.14 | -9.75 | 13.12 |
| Net Income | -55.18 | -30.06 | -21.56 | -16.95 | -14.76 | -6.61 | -9.97 | -7.00 | -8.53 | 10.90 |
| Shares Outstanding | 12.00 | 11.21 | 3.42 | 0.78 | 0.30 | 0.02 | 0.02 | 0.32 | 0.30 | 0.27 |
| Earnings Per Share | -4.60 | -2.68 | -7.45 | -21.75 | -49.99 | -269.84 | -409.33 | -22.05 | -28.35 | 37.80 |
| Operating Cash Flow | -43.61 | -28.55 | -19.94 | -18.47 | -19.12 | -6.39 | -6.27 | -64.24 | -83.72 | 138 |
| Capital Expenditures | -0.06 | -0.38 | -0.02 | 0.42 | -0.27 | 0.10 | -0.04 | 1.26 | -1.43 | -3.27 |
| Free Cash Flow | -43.68 | -28.93 | -19.96 | -18.05 | -19.39 | -6.29 | -6.32 | -62.98 | -85.14 | 135 |
| Cash & Equivalents | 76.87 | 120 | 37.78 | 36.53 | 66.43 | 1.87 | 92.33 | 125 | 195 | 214 |
| Total Debt | 1.80 | - | 5.09 | 19.40 | 33.74 | - | 1.14 | 1.99 | 3.23 | 3.06 |
| Net Cash / Debt | 75.06 | 120 | 32.69 | 17.13 | 32.68 | 1.87 | 91.19 | 123 | 192 | 211 |
| Assets | 98.55 | 125 | 39.51 | 38.09 | 69.52 | 2.98 | 146 | 190 | 258 | 263 |
| Liabilities | 30.22 | 4.98 | 8.74 | 22.02 | 38.10 | 3.46 | 11.26 | 13.66 | 83.84 | 171 |
| Book Value | 68.34 | 120 | 30.77 | 16.07 | 31.43 | -109 | 135 | 176 | 174 | 91.85 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Catalyst Biosciences, Inc. |
| Country |
United States |
| Employees |
34 |
| CEO |
Nassim Usman |
Stock Information
| Ticker Symbol |
CBIO |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CBIO |
Description
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing various treatments for hemophilia and other rare bleeding disorders using its potent subcutaneous (SQ) coagulation factors that promote blood clotting. Its engineered coagulation factors are designed to overcome the limitations of current intravenous (IV) treatment options, facilitate prophylaxis, and ultimately deliver substantially better outcomes for patients using SQ dosing. Its products include Marzeptacog alfa (activated), a subcutaneously administered next-generation engineered coagulation Factor VIIa that has completed Phase II development for individuals with hemophilia A or B with inhibitors; and Dalcinonacog alfa, a next-generation engineered coagulation Factor IX therapy that has completed Phase IIb clinical trials for the treatment of hemophilia B. The company also develops CB 2679d-GT, an early stage Factor IX gene therapy construct for Hemophilia B; CB 2782-PEG, a long acting anti-C3 protease for the treatment of dry age-related macular degeneration (AMD); and SQ systemic complement inhibitors pipeline. The company has a strategic research collaboration with Mosaic Biosciences, Inc. to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other serious inflammatory retinal diseases; and license and collaboration agreement with Biogen International GmbH for the development and commercialization of pegylated CB 2782 (anti-C3 protease) to treat geographic atrophy associated dry AMD. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.